Brendon Neuen's Publications

About Brendon Neuen's Publications

Program Lead, Renal and Metabolic
  • Nephrologist and Director, Kidney Trials, Royal North Shore Hospital
  • Clinical Associate Professor, University of Sydney
  • Conjoint Associate Professor, UNSW Sydney
  • Ph.D. ,
  • MBBS(Hons),
  • MSc(Oxon),
  • FRACP,
  • FASN

  • External Validation of a Machine Learning Model for Progression of CKD in the CREDENCE and CANVAS Trials

    Date published:

  • Design and Baseline Characteristics of the FIND-CKD Trial: Efficacy of Finerenone on Kidney Disease Progression in People with Non-Diabetic CKD

    Date published:

  • Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: insights from the CANVAS Program and CREDENCE trial

    Date published:

  • Iron Biomarkers and Effects of Canagliflozin in Patients with Type 2 Diabetes and CKD: A Post Hoc Analysis of the CREDENCE Trial

    Date published:

  • Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients with Type 2 Diabetes and CKD: A Post Hoc Analysis of the CREDENCE Trial

    Date published:

  • Kidney outcomes in heart failure trials: does endpoint definition matter?

    European Journal of Heart Failure Date published:

  • Improving outcomes in cardio-renal-metabolic diseases

    Journal of Cardiac Failure Date published:

  • Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

    The Lancet Date published:

  • Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

    Diabetes Care Date published:

  • Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure

    European Journal of Heart Failure Date published:

  • Endothelin Receptor Antagonists and Risk of Heart Failure in CKD

    JACC: Heart Failure Date published:

  • Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis

    Diabetes, Obesity and Metabolism Date published:

  • 862-P: Interleukin-6 and Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Post Hoc Analysis of CANVAS Trial

    Diabetes Date published:

  • Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials

    Circulation Date published:

  • Risk factors for incident kidney disease in older adults: an Australian prospective population-based study

    Internal Medicine Journal Date published:

  • Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published: